NA-Semax
Synthetic ACTH Analog | Nootropic & Neuroprotective Peptide
DoseGear research brief
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH) fragment 4-10, originally developed in Russia for stroke recovery. It achieves enhanced CNS penetration through direct transport via olfactory epithelium and trigeminal nerves, bypassing the blood-brain barrier.
Rapidly increases BDNF levels, modulates dopaminergic and serotonergic systems, and achieves direct brain delivery through olfactory transport with 0. 093% blood-brain barrier penetration (vs 0. 01% IV).
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Synthetic ACTH-fragment-related peptide developed in Russian research.
Neuroprotection, stroke rehabilitation, and cognition research with proposed neurotrophin and neural-network effects.
Not reported for an attributable injectable-vial response window in the reviewed evidence.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
A Nootropic Adrenocorticotropin Analog 4-10 Semax: 15 Years Experience in Its Design and Study
The Efficacy of Semax in the Treatment of Patients at Different Stages of Ischemic Stroke
Effects of Semax on the Default Mode Network of the Brain
The Peptide Semax Affects the Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischemia: Genome-Wide Transcriptional Analysis
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
